進階篩選

Technical category
技術研發單位
    • 5D智慧城市─SmartES平台

      AI & IOT Application FutureTech 5D智慧城市─SmartES平台

      NCREE has originally developed 5D digital space—on the basis of 3D city modelsconnections of different kinds of sensors around the world— is an online to offline virtual space with a combination of rising 5G technology advantages. Collectingreorganizing various 3D cartographic data with Building Information Modeling (BIM), satellite imagery, UAV 3D modeling, LiDar point cloud data, etc., can increase the diversity of the buildinglandscape. 5D+5G smart city platform would accelerate the 5D smart city to become the digital twin of a real city.
    • 突破物聯網的最後一哩:無晶片射頻辨識

      Electronic & Optoelectronics FutureTech 突破物聯網的最後一哩:無晶片射頻辨識

      The major cost of conventional RFID tags comes from a microchip. To reduce the start-up cost, we develop a chipless RFID system that eliminates the use of the chip. This research organize the real-world issues of chipless RFID into four subjects, including the design of chipless tags, chipless RFID readers, reader signal processing,wireless propagation channel. We successfully integrate the four topics, developing a calibration-free, orientation-insensitive,high-capacity chipless RFID system with multi-tag detection capability.
    • First-in-class anti-diabetic drug, PS1

      Precision Health Ecosystem FutureTech First-in-class anti-diabetic drug, PS1

      Diabetes is now still an incurable disease. Beta cell failure is one of common causes. No drugs for this failure have been developed. This invention is to developapply PS1 to treatreverse diabetes. PS1 is a first-in-class small-molecule drug, which targets beta cells by improving their survivalfunction. As a result, PS1 can treatreverse diabetes. The anti-diabetic mechanism of
    • BPR1R系列:新穎集落刺激因子1受體抑制劑作為癌症免疫調節劑

      FutureTech BPR1R系列:新穎集落刺激因子1受體抑制劑作為癌症免疫調節劑

      We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.